MedTrace Logo

Effect of Topical Nepafenac 0.1% on Pain Related to Intravitreal Injections

NCT02821390 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2017-05-05

No results posted yet for this study

Summary

The analgesic effect of Nepafenac 0.1% Ophthalmic Drops on ocular pain related to intravitreal injections will be evaluated.

Pain perception will be assessed by the Short Form of the McGill Pain Questionnaire.

Conditions

Interventions

DRUG

Nepafenac Eye Drops

One drop instilled to the eye's cul de sac prior to the intravitreal injection.

DRUG

Placebo (Artificial Tears)

One drop instilled to the eye's cul de sac prior to the intravitreal injection

Sponsors & Collaborators

  • University Hospital of Patras

    lead OTHER

Principal Investigators

  • Constantine D Georgakopoulos, MD, Phd · Associate Professor of Ophthalmology, Medical School, University of Patras, Greece

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2017-01-31
Completion
2017-01-31

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02821390 on ClinicalTrials.gov